Welcome to our dedicated page for LB Pharmaceuticals news (Ticker: LBRX), a resource for investors and traders seeking the latest updates and insights on LB Pharmaceuticals stock.
LB Pharmaceuticals Inc develops novel therapies for neuropsychiatric diseases, led by LB-102, an oral investigational small molecule and benzamide antipsychotic candidate for schizophrenia, bipolar depression and adjunctive major depressive disorder. Company news frequently centers on LB-102 clinical data, peer-reviewed publications, medical-conference presentations and trial-program updates across schizophrenia and mood-disorder indications.
Other recurring updates include financial results, capital-raising activity, board and executive appointments, Nasdaq inducement grants and healthcare-conference participation. These announcements frame the company's single-segment biopharmaceutical model around clinical development, financing needs and governance as it advances LB-102.
LB Pharmaceuticals (Nasdaq:LBRX) reported Q1 2026 results and a clinical and corporate update. The company initiated the pivotal Phase 3 NOVA-2 trial in schizophrenia, Phase 2 ILLUMINATE-1 in bipolar 1 depression, and a 52-week NOVA-3 safety study, and published Phase 2 NOVA-1 data in JAMA Psychiatry.
LB Pharmaceuticals closed a $100 million private placement, with net proceeds of $93.8 million, and plans a Phase 2 adjunctive MDD trial in early 2027. Q1 2026 R&D expenses were $14.6 million and G&A expenses $7.5 million, leading to a $19.1 million net loss. Cash, cash equivalents, and marketable securities totaled $365.6 million, expected to fund operations into Q2 2029.
LB Pharmaceuticals (Nasdaq: LBRX) announced publication in JAMA Psychiatry of Phase 2 NOVA-1 results for LB-102 in adults with acute schizophrenia. The trial showed statistically significant benefit versus placebo, rapid onset at week 1, sustained effect at endpoint, and a favorable safety profile. The pivotal Phase 3 NOVA-2 trial (approx. 460 patients, 6 weeks, ~25 U.S. sites) is ongoing with topline data expected in 2H 2027.
LB Pharmaceuticals (Nasdaq: LBRX) announced that CEO Heather Turner will present at the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026 at 11:45 a.m. ET. A live webcast and replay will be available on the company’s Investors > Events webpage.
The presentation provides an opportunity to hear management discuss business progress and strategy for LB Pharmaceuticals' late-stage neuropsychiatric therapy programs.
LB Pharmaceuticals (Nasdaq: LBRX) presented new Phase 2 NOVA-1 analyses at SIRS on March 27, 2026, showing LB-102 produced a statistically significant, dose-dependent improvement in global cognition that was primarily a direct drug effect rather than secondary to overall symptom change.
LB-102 is a once-daily oral selective D2/D3/5HT7 antagonist that showed benefit versus placebo across PANSS Marder factors, rapid onset at week 1, sustained effects through endpoint, and a favorable safety profile with low EPS, minimal sedation, and few GI side effects. The company plans cognition as a secondary endpoint in pivotal NOVA-2 and other trials.
LB Pharmaceuticals (Nasdaq: LBRX) reported positive Phase 2 results for LB-102 in acute schizophrenia and advanced LB-102 into late-stage development, initiating a Phase 3 NOVA-2 trial (topline H2 2027) and a Phase 2 bipolar depression trial (ILLUMINATE-1; topline Q1 2028).
The company completed an IPO raising $327.8 million, added a $100 million private placement, and reported cash, cash equivalents, and investments of $295.2 million as of December 31, 2025—expected to fund operations into Q2 2029.
LB Pharmaceuticals (Nasdaq: LBRX) initiated its pivotal Phase 3 trial NOVA-2 of LB-102 for schizophrenia on March 25, 2026. NOVA-2 will randomize ~460 patients 1:1:1 to 50 mg, 100 mg, or placebo for six weeks; primary endpoint is change in PANSS total score at Week 6.
Secondary endpoints include negative symptoms, cognitive performance, CGI-S, Marder factors, and PSP. An ~900-patient open-label extension is planned. Topline data are expected in 2H 2027; a pre-NDA meeting with FDA is expected if results are positive.
LB Pharmaceuticals (Nasdaq: LBRX) appointed Robert Lenz, M.D., Ph.D. to its Board of Directors on March 9, 2026. Dr. Lenz brings over 20 years of neuroscience R&D leadership, including senior roles at Neumora Therapeutics and Amgen, and a track record overseeing drug development through regulatory approval.
The appointment is positioned to support advancement of LB-102 into late-stage clinical development across multiple neuropsychiatric indications.
LB Pharmaceuticals (Nasdaq: LBRX) announced management will present at two investor events in March 2026: the Leerink 2026 Global Healthcare Conference on March 11, 2026 at 1:40 p.m. ET and the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 2:30 p.m. ET.
A live webcast and archived replay will be available in the Investors > Events section of the company website at https://lbpharma.us/.
LB Pharmaceuticals (Nasdaq: LBRX) granted an inducement equity award to new General Counsel Dr. Minako Pazdera on February 10, 2026 under the Nasdaq Listing Rule 5635(c)(4) exception.
Dr. Pazdera received options to buy 140,000 shares, with a 10-year term, $24.22 exercise price (closing price on grant date) and four-year vesting (25% after one year, then monthly).
LB Pharmaceuticals (Nasdaq: LBRX) entered a securities purchase agreement to sell 3,306,571 shares of common stock and pre-funded warrants to purchase up to 1,417,107 shares at $21.17 per share (pre-funded warrant price $21.1699), anticipating approximately $100.0 million gross proceeds.
The private placement is expected to close on or about February 6, 2026, includes major institutional investors, and names Leerink Partners, Piper Sandler and Stifel as placement agents. Proceeds are intended to fund a Phase 2 trial of LB-102 in major depressive disorder and for working capital; resale registration rights were agreed with investors.